A handful of viruses have been associated with long-term, debilitating symptoms in a subset of those who become infected. Early signs hint that SARS-CoV-2 may do the same.
Dozens of intranasally delivered vaccines targeting SARS-CoV-2 are in development. Could they pave the way for widespread nasal vaccination in the future?
Several lines of evidence suggest that targeting the body’s defense pathways might help treat a subset of people with the psychiatric disorder. But many open questions remain.